What was Evolus Q2 2026 revenue growth?

Evolus reported 21% year-over-year revenue growth in Q2 2026, exceeding internal guidance. The company subsequently raised its full-year 2026 revenue outlook, signaling sustained demand for Jeuveau toxin and its filler portfolio.

Is Evolus profitable?

Yes, Evolus has posted three consecutive profitable quarters as of Q2 2026. This profitability combined with accelerating revenue growth marks an inflection point for the independent injectable platform.

What is Evolus' strategy to compete with AbbVie and Galderma?

Evolus uses bundled toxin-filler pricing and the Evolus Rewards loyalty program to attract practices seeking alternatives to larger competitors. The company's direct manufacturing footprint and supply-chain control also provide margin advantages over pure-play distributors.

Should med spas consider switching to Evolus for injectables?

For high-volume practices, Evolus is now a credible third option in toxin sourcing, particularly if rebate leverage and supply reliability are priorities. The company's recent profitability and raised guidance suggest stable supply and competitive pricing power.

What are Evolus' main products?

Evolus' primary products are Jeuveau (toxin) and its Evolus filler portfolio. The company bundles these products together with pricing incentives and a loyalty rewards program to drive adoption.

Monday, August 24, 2026 Never miss a recall or a rule change Go Pro · $20/mo →

RegulatoryAbbVie Launches Phase 2 Forehead Lines Studytoday MarketFacial Rejuvenation Market Forecast to Hit $5.66B by 20302 days ago Business & M&AAllergan Aesthetics Overhauls Loyalty Programtoday Devices & TechXERF Technology Enters Australian Market for Skin Tightening2 days ago Business & M&AEvolus Expands Estyme to Canada, Australia, New Zealandtoday MarketArm Fat Now Top Body Sculpting Concern in Singapore2 days ago Devices & TechSofwave Hits One Million Treatments Milestonetoday RegulatoryCKD Bio Pursues China Botox Approval—2027 Launch Targeted2 days ago RegulatoryRevance Wins FDA Nod for Under-Eye Injectablesyesterday MarketGLP-1 Pill Era Is Forcing Beauty Market Shiftyesterday InjectablesAEON Releases Expanded ABP-450 Botox Biosimilar Datayesterday Devices & TechUltherapy PRIME Real-Time Imaging Reshapes Midface Liftingyesterday

Business & M&A

Evolus Q2 Revenue Beats Forecast, Raises 2026 Outlook

The injectable platform company posts 21% revenue growth and signals sustained momentum in toxin and filler.

By Evan at Inside MedSpa · Aug 21, 2026

1-YEAR MOVE

EOLS ▼15.6% ABBV ▲11.6%

1-year price move by ticker
Ticker	Company	1-year change
EOLS	Evolus	−15.6%
ABBV	AbbVie (Allergan Aesthetics)	+11.6%

Evolus reported Q2 2026 revenue that exceeded internal guidance, with top-line growth of 21% year-over-year. The company has raised its full-year 2026 revenue outlook, signaling confidence in sustained demand for its Jeuveau toxin and Evolus filler portfolio.

Inside MedSpa Pro

You've reached your free articles this week.

Keep reading every article, unlock the full trackers, and get the twice-a-week intelligence brief — from $20/mo, or $200/yr (two months free). Never miss a recall or a rule change.

Every article, unlocked — no weekly limit
The full 50-state law tracker, stock & M&A watch
The twice-a-week, 2-minute intelligence brief
Recalls, FDA clearances & safety signals as they hit

See everything you get →

Cancel anytime, one click · 14-day money-back on annual

https://insidemedspa.com/article/evolus-q2-revenue-beats-guidance/

Discussion

Free alerts

Get flagged before it costs you.

We'll flag the moment a recall or rule change hits your practice. One email a week, one click to leave.

Free · weekly · unsubscribe anytime. Privacy.

This morning's brief · 6 AM

The free version stops here.

What today's moves mean for your margins — and exactly what to do — already went out to Pro. By the time the trade press explains it, the window to act has closed.

Go Pro · $20/mo Two minutes a morning. Cancel anytime.

Live · Market movers

STRATA Skin Sciences-50%Hims & Hers Health+6.03%Estée Lauder+6.02%Bausch Health (Solta)-5.43%The Beauty Health Company (HydraFacial)+3.65%

The full stock & M&A watch →

FDA Activity — Aesthetic Devices

Monthly 510(k) clearances vs. recalls.

510(k) clearances Recalls

FDA Activity — Aesthetic Devices — Monthly 510(k) clearances vs. recalls.
Month	510(k) clearances	Recalls
Jun '25	0	4
Jul '25	0	1
Sep '25	0	1
Oct '25	0	2
Jan '26	0	1
Feb '26	0	5
Mar '26	0	5
Apr '26	0	19
May '26	7	18
Jun '26	34	8
Jul '26	23	4
Aug '26	5	0

The 50-state regulation tracker →

Inside MedSpa Pro

By the time it's news, it's too late.

The rebate cut, the scope-of-practice bill, the competitor opening down the street — it hits your business before the trade press ever covers it. Pro gets you there first: what happened, why it touches your margins, and exactly what to do — at 6 AM, in two minutes.

Go Pro · $20/mo Never miss a recall or a rule change. Cancel anytime.

The twice-a-week intelligence brief Go Pro · $20/mo →

Evolus Q2 Revenue Beats Forecast, Raises 2026 Outlook

Share

Discussion

Leave a comment

By the time it's news, it's too late.